Location History:
- Funabashi, JP (2006)
- Chiba, JP (1988 - 2012)
- Tokyo, JP (1987 - 2021)
Company Filing History:
5 out of 104 
4 out of 441 
3 out of 2,637 
Years Active: 1987-2021
Title: **Kiyoshi Nakayama: Innovator in Pharmaceutical Chemistry**
Introduction
Kiyoshi Nakayama, based in Tokyo, JP, is a notable inventor with a remarkable portfolio of 22 patents. His contributions to the field of pharmaceutical chemistry center around the development of innovative compounds that promise advancements in medical treatments.
Latest Patents
Among his latest patents are the following groundbreaking inventions:
1. **Amino-pyrrolopyrimidinone Compounds and Methods of Use Thereof** - This patent pertains to a compound of Formula (I) and includes a variety of acceptable forms such as salts and prodrugs. This invention aims to modulate the activity of BTK (Bruton’s tyrosine kinase) and offers a method for treating or preventing diseases associated with BTK.
2. **Tetrahydropyranyl Amino-pyrrolopyrimidinone and Methods of Use Thereof** - Similar to the first, this patent elaborates on a compound of Formula (I) with various acceptable forms. This too targets the modulation of BTK activity, presenting a unique pharmaceutical composition and method for disease prevention related to BTK.
Career Highlights
Kiyoshi Nakayama has contributed substantially to the pharmaceutical sector through his work with prestigious companies such as Arqule, Inc. and Daiichi Sankyo Company, Limited. His innovative work is not only recognized through patents but also through the tangible impact of his research on drug development.
Collaborations
Throughout his career, Kiyoshi has collaborated with esteemed colleagues such as Hiroaki Inagaki and Jean-Marc Lapierre. These partnerships have likely fostered an environment of creativity and innovation, further enhancing the efficacy of his research and inventions.
Conclusion
Kiyoshi Nakayama remains a prominent figure in the realm of pharmaceutical inventions, with his work on BTK-modulating compounds paving the way for future medical advancements. His dedication to innovation and collaboration continues to significantly impact the pharmaceutical industry.